Scribd
Upload
69 views3 pages

Naresh Kapoor

Jubilant Pharmova Limited announced that its wholly owned subsidiary Jubilant Draximage Inc. received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its radiopharmaceuticals manufacturing facility in Montreal, Canada following an inspection from June 6-10, 2022. With the receipt of the EIR, the inspection stands successfully closed. Jubilant Pharmova is an integrated global pharmaceutical company engaged in manufacturing and supply of radiopharmaceuticals, allergy immunotherapy products, contract manufacturing of injectables, and solid dosage formulations through five manufacturing facilities serving markets including the US, Europe and others.

Uploaded by

Manan Agarwal
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
69 views3 pages

Naresh Kapoor

Jubilant Pharmova Limited announced that its wholly owned subsidiary Jubilant Draximage Inc. received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its radiopharmaceuticals manufacturing facility in Montreal, Canada following an inspection from June 6-10, 2022. With the receipt of the EIR, the inspection stands successfully closed. Jubilant Pharmova is an integrated global pharmaceutical company engaged in manufacturing and supply of radiopharmaceuticals, allergy immunotherapy products, contract manufacturing of injectables, and solid dosage formulations through five manufacturing facilities serving markets including the US, Europe and others.

Uploaded by

Manan Agarwal
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 3

August 26, 2022

BSE Limited National Stock Exchange of India Limited


P. J. Towers, 25th Floor, Exchange Plaza, 5th Floor,
Dalal Street, Bandra-Kurla Complex,
Mumbai - 400 001 Bandra (E)
Mumbai - 400 051

Scrip Code: 530019 Symbol: JUBLPHARMA

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,
we enclose herewith a press release pertaining to receipt of Establishment Inspection Report (EIR) with
Voluntary Action Indicated (VAI) status from the USFDA for radiopharmaceuticals manufacturing facility
of subsidiary company Jubilant Draximage Inc., at Montreal Canada.

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited
Digitally signed
Naresh byKapoor
Naresh

Kapoor Date: 2022.08.26


20:32:25 +05'30'

Naresh Kapoor
Company Secretary

Encl.: as above
Jubilant Pharmova Limited
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
PRESS RELEASE www.jubilantpharmova.com

Noida, Friday, August 26, 2022

Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility
Montreal Canada

Jubilant Pharmova Limited, an integrated global Pharmaceutical Company, today announced that Jubilant
Draximage Inc., a wholly owned subsidiary of the Company has received the Establishment Inspection Report (EIR)
with Voluntary Action Indicated (VAI) status from the USFDA for its radiopharmaceuticals manufacturing facility
at Montreal Canada in respect of the inspection conducted by the regulatory agency from June 6, 2022 to June
10, 2022.

With the receipt of the EIR, the inspection stands successfully closed.

About Jubilant Pharma Limited


Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned
subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in
manufacturing and supply of Radiopharmaceuticals with a network of radio-pharmacies in the US, Allergy
Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage
Formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe
and other geographies. The Company has a team of around 3,500 multicultural people across the globe and is
committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner
of Choice' by leading pharmaceutical companies globally. For more info please visit www.jubilantpharma.com

About Jubilant Pharmova Limited


Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals,
Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business
through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals
with a network of radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile
Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that
cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides
contract research and development services through two world class research centers in Bangalore and Noida in
India. Jubilant Pharmova Limited is also involved in manufacturing of Active Pharmaceutical Ingredients from its
USFDA approved facility in Nanjagud, India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business
and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and
auto-immune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe.
The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more
information, please visit: www.jubilantpharmova.com
For more information, please contact:

For Investors
Vineet V Mayer / Surajit Pal
Ph: +91 120 436 1103 / 1002
E-mail:vineet.mayer@jubl.com, Surajit.pal1@jubl.com

Disclaimer
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about
plans and objectives, the progress and results of research and development, potential product characteristics and uses,
product sales potential and target dates for product launch are forward-looking statements based on estimates and the
anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks
and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those
anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral
forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its
reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results,
changed assumptions or other factors.

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy